Interim analysis of a phase III of zanubrutinib vs ibrutinib shows improved response rates, 12 month PFS and better safety with zanubrutinib. There was decreased major bleeding, cardiac events and AEs leading to discontinuation. Afib was lower at 2.5% vs 10%.
Read the full article here
Background and ObjectivesThe time taken to achieve blood pressure (BP) control could be pivotal in the benefits of reducing BP in acute intracerebral hemorrhage (ICH).…
AHRQ advances excellence in healthcare by producing evidence to make healthcare safer, higher quality, more accessible, equitable, and affordable.
The Arthroscopy Association of North America’s Annual Meeting is the world’s largest arthroscopy-focused event of the year. Join AANA and colleagues from around the world…
prostate cancer, grade group 2 prostate cancer, ProtecT trial, International Society of Urological Pathologists (ISUP), ISUP grading system, radical prostatectomy, low-grade prostate cancer.
Many cases of CVD are preventable, so nursing staff in all settings need to know the basics
This study evaluated the topics, accuracy, and credibility of X (formerly Twitter) Community Notes addressing COVID-19 vaccination.
This study evaluated the topics, accuracy, and credibility of X (formerly Twitter) Community Notes addressing COVID-19 vaccination.
Click on the city or the Register To Attend button below. Some city pages are still being developed.
Investigators of the phase 3 ALINA trial report no unexpected safety findings with alectinib in ALK-positive non–small cell lung cancer.
